A major insurance company and a clinical trial technology firm have formed a new alliance aimed at preventing a hidden but dangerous problem in medical research: patients enrolling in multiple studies at once. The partnership between Chubb and Verified Clinical Trials seeks to catch duplicate enrollments and other protocol violations before they can compromise patient safety or skew study results.
Verified Clinical Trials operates a secure global registry that checks potential study participants against a database of current and past enrollments in real time. When a person tries to join a new trial, the system flags them if they are already active in another study or have a history of undisclosed participation. This matters because being in two trials at once can expose patients to conflicting treatments, increase the risk of adverse events, and corrupt the data that regulators rely on to approve new drugs. The technology is designed to catch these issues at the screening stage, before a patient is enrolled.
Under the alliance, Chubb which is the leading global underwriter of clinical trial insurance will offer its clients access to this registry as an additional risk management tool. The goal is to reduce preventable risks such as serious adverse events, protocol deviations, and compromised data quality that stem from duplicate or hidden study participation. The companies say that combining insurance expertise with real time subject verification creates a proactive safety net rather than a reactive one.
“Research subject safety and data integrity are fundamental to every successful clinical trial,” said Dr. Mitchell Efros, CEO of Verified Clinical Trials. “This alliance represents an important opportunity to help bring greater protection, stronger oversight, and added value to the clinical research ecosystem.” Lee Farrow, executive vice president at Chubb, noted that the inability to reliably check a participant’s research history has been a longstanding and underrecognized challenge in the field.
The partnership is expected to benefit not only sponsors, contract research organizations, and study sites, but also the patients who volunteer for trials. By catching duplicate enrollments early, the system can help ensure that each participant receives the correct treatment and that the final study data is clean and trustworthy. The companies see this as a step toward safer, more efficient drug development, with the ultimate goal of bringing new therapies to patients with greater confidence.